HomeCompareLZAGY vs CHD

LZAGY vs CHD: Dividend Comparison 2026

LZAGY yields 0.76% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LZAGY wins by $3.3K in total portfolio value· pulled ahead in Year 7
10 years
LZAGY
LZAGY
● Live price
0.76%
Share price
$63.41
Annual div
$0.48
5Y div CAGR
39.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.7K
Annual income
$2,840.75
Full LZAGY calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — LZAGY vs CHD

📍 LZAGY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGY
Annual income on $10K today (after 15% tax)
$64.35/yr
After 10yr DRIP, annual income (after tax)
$2,414.64/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, LZAGY beats the other by $1,316.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGY + CHD for your $10,000?

LZAGY: 50%CHD: 50%
100% CHD50/50100% LZAGY
Portfolio after 10yr
$28.0K
Annual income
$2,066.62/yr
Blended yield
7.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

LZAGY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
7/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGY buys
2
CHD buys
0
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$LZAGY▼ Sell$1,001 - $15,0002023-12-21
Josh Gottheimer🏢 House$LZAGY▼ Sell$1,001 - $15,0002023-12-05
Daniel Goldman🏢 House$LZAGY▼ Sell$15,001 - $50,0002023-07-10
Josh Gottheimer🏢 House$LZAGY▼ Sell$1,001 - $15,0002021-04-13
Peter Meijer🏢 House$LZAGY▼ Sell$15,001 - $50,0002021-02-17
Peter Meijer🏢 House$LZAGY▼ Sell$1,001 - $15,0002021-01-28
Greg Gianforte🏢 House$LZAGY▲ Buy$15,001 - $50,0002020-01-13
Donna Shalala🏢 House$LZAGY▼ Sell$1,001 - $15,0002019-06-24
Greg Gianforte🏢 House$LZAGY▲ Buy$100,001 - $250,0002018-05-14
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGYCHD
Forward yield0.76%1.27%
Annual dividend / share$0.48$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.3%23.1%
Portfolio after 10y$29.7K$26.4K
Annual income after 10y$2,840.75$1,292.51
Total dividends collected$8.7K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: LZAGY vs CHD ($10,000, DRIP)

YearLZAGY PortfolioLZAGY Income/yrCHD PortfolioCHD Income/yrGap
1$10,805$105.46$10,856$156.32$51.00CHD
2$11,710$148.35$11,811$195.24$101.00CHD
3$12,739$209.30$12,883$244.38$144.00CHD
4$13,927$296.42$14,091$306.64$164.00CHD
5$15,324$421.90$15,463$385.88$139.00CHD
6$17,001$604.34$17,033$487.17$32.00CHD
7← crossover$19,064$872.88$18,843$617.36+$221.00LZAGY
8$21,673$1,274.26$20,947$785.72+$726.00LZAGY
9$25,076$1,885.93$23,419$1,004.91+$1.7KLZAGY
10$29,672$2,840.75$26,350$1,292.51+$3.3KLZAGY

LZAGY vs CHD: Complete Analysis 2026

LZAGYStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this LZAGY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGY vs SCHDLZAGY vs JEPILZAGY vs OLZAGY vs KOLZAGY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.